IL-35-Mediated Immunotherapy for Type I and Autoimmune Diabetes Mellitus
The Hidden Risks of Sitting for 8+ Hours
IL-35 therapy targets immune responses, offering hope for Type 1 Diabetes patients.
How IL-35 Works?
IL-35 regulates T-cells to reduce inflammation in autoimmune diabetes.
Benefits for Type 1 Diabetes
May improve insulin levels by balancing immune reactions in pancreatic cells.
Advances in Autoimmune Therapy
IL-35 offers a novel approach, reducing dependency on traditional treatments.
Targeting Immune Responses
Modulates immune cells to prevent destructive attacks on pancreatic beta cells.
Potential for Widespread Use
Could benefit other autoimmune conditions, not just diabetes.
The Future of IL-35 in Medicine
Research is ongoing, aiming to make IL-35 treatments widely available.
Sitting over 8 hours daily can raise health risks even after exercise
Read More